ATIM-08. IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE I CLINICAL TRIAL

As part of a phase 1, dose-escalation, biological-endpoint clinical study (NCT00805376) of DNX-2401 (Delta-24-RGD), a Rb-targeted, tumor-selective, replication-competent oncolytic adenovirus, conducted in 37 patients with recurrent malignant glioma, 12 patients received an intratumoral injection thr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Fueyo, Juan, Gomez-Manzano, Candelaria, Villalobos, Paloma, Rodriguez-Canales, Jaime, Wistuba, Ignacio, Hess, Kenneth R, Alonso, Marta M, Tejada, Sonia, Valle, Ricardo Diez, Ewald, Brett, Tufaro, Frank, Lang, Fred
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692270/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.104
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi